MTOR and hepatocellular carcinoma: Smad4 was reported to promote HCC by suppressing CD8+ T cell infiltration and glycolytic activity through the CXCL10/mammalian target of rapamycin (mTOR)/lactate dehydrogenase A (LDHA) pathway (Xin et al., 2024).